Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexS&P 500 P/E25.02 EPS (ttm)1.49 Insider Own0.05% Shs Outstand5.56B Perf Week2.87%
Market Cap203.11B Forward P/E12.94 EPS next Y2.88 Insider Trans-6.06% Shs Float5.55B Perf Month10.82%
Income8.36B PEG- EPS next Q0.48 Inst Own70.20% Short Float1.20% Perf Quarter3.63%
Sales48.65B P/S4.18 EPS this Y62.30% Inst Trans-2.39% Short Ratio1.99 Perf Half Y10.79%
Book/sh11.74 P/B3.17 EPS next Y1.55% ROA5.00% Target Price41.78 Perf Year1.70%
Cash/sh1.92 P/C19.35 EPS next 5Y-1.00% ROE13.50% 52W Range26.42 - 39.79 Perf YTD0.27%
Dividend1.52 P/FCF97.18 EPS past 5Y14.70% ROI14.70% 52W High-6.44% Beta0.66
Dividend %4.08% Quick Ratio1.10 Sales past 5Y0.90% Gross Margin80.10% 52W Low40.91% ATR1.11
Employees88300 Current Ratio1.40 Sales Q/Q-4.30% Oper. Margin13.30% RSI (14)60.35 Volatility1.82% 2.93%
OptionableYes Debt/Eq0.97 EPS Q/Q-71.30% Profit Margin17.90% Rel Volume0.75 Prev Close36.53
ShortableYes LT Debt/Eq0.76 EarningsOct 27 BMO Payout95.80% Avg Volume33.51M Price37.23
Recom2.60 SMA204.46% SMA505.91% SMA2008.97% Volume25,271,277 Change1.92%
Nov-19-20Resumed Goldman Neutral $40
Nov-10-20Resumed Bernstein Mkt Perform $42
Oct-12-20Downgrade Atlantic Equities Overweight → Neutral $44 → $39
Sep-29-20Initiated Berenberg Hold $38
Jun-16-20Initiated SVB Leerink Mkt Perform $40
Feb-27-20Upgrade Standpoint Research Hold → Buy
Feb-27-20Initiated Barclays Equal Weight $36
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Outperform $46
Oct-17-19Resumed BofA/Merrill Neutral $37
Jul-30-19Downgrade Morgan Stanley Overweight → Equal-Weight $48 → $40
Jul-30-19Downgrade BofA/Merrill Buy → Neutral
Jun-04-19Resumed Morgan Stanley Overweight $48
Feb-20-19Resumed Citigroup Neutral $41
Jan-31-19Upgrade Credit Suisse Neutral → Outperform
Jan-31-19Upgrade Argus Hold → Buy
Jan-23-19Downgrade UBS Buy → Neutral
Dec-11-18Downgrade JP Morgan Overweight → Neutral
Nov-01-18Downgrade BMO Capital Markets Outperform → Market Perform
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Nov-29-20 09:06AM  
06:25AM  
Nov-28-20 08:53AM  
08:07AM  
07:30AM  
06:10AM  
02:41AM  
Nov-27-20 04:41PM  
04:38PM  
01:27PM  
01:24PM  
01:10PM  
12:00PM  
11:06AM  
10:05AM  
10:03AM  
09:21AM  
09:11AM  
08:52AM  
07:45AM  
06:28AM  
05:33AM  
Nov-26-20 03:21PM  
09:28AM  
08:29AM  
07:18AM  
02:00AM  
12:14AM  
Nov-25-20 05:31PM  
05:30PM  
04:39PM  
04:17PM  
03:36PM  
03:14PM  
12:48PM  
11:49AM  
10:35AM  
10:16AM  
10:08AM  
09:49AM  
09:40AM  
08:46AM  
08:40AM  
08:08AM  
08:00AM  
08:00AM  
07:43AM  
07:30AM  
06:55AM  
06:45AM  
06:00AM  
01:18AM  
Nov-24-20 05:35PM  
05:25PM  
04:05PM  
02:39PM  
01:56PM  
01:36PM  
01:21PM  
12:10PM  
11:59AM  
11:45AM  
11:44AM  
11:39AM  
11:27AM  
11:04AM  
10:53AM  
10:32AM  
10:20AM  
10:14AM  
09:21AM  
09:00AM  
08:38AM  
08:10AM  
07:40AM  
07:30AM  
07:27AM  
06:45AM  
06:37AM  
06:31AM  
06:05AM  
04:57AM  
04:47AM  
04:32AM  
01:03AM  
Nov-23-20 10:12PM  
06:28PM  
06:05PM  
06:00PM  
05:42PM  
05:17PM  
04:13PM  
04:08PM  
04:06PM  
02:02PM  
02:01PM  
12:49PM  
11:31AM  
11:12AM  
10:59AM  
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; a material transfer and collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; a drug discovery collaboration with Sosei Group Corporation; and collaboration with LianBio. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOURLA ALBERTChairman & CEONov 09Sale41.94132,5085,557,38678,273Nov 10 05:55 PM
SUSMAN SALLYExecutive Vice PresidentNov 09Sale41.9443,6621,831,184108,096Nov 10 05:55 PM
PFIZER INC10% OwnerOct 27Buy10.001,200,00012,000,00027,349,211Oct 29 05:44 PM
BLAYLOCK RONALD EDirectorAug 06Buy38.5513,000501,08513,000Aug 10 08:07 AM
DAMICO JENNIFER B.SVP & ControllerJun 05Sale36.132,18178,8007,542Jun 08 04:29 PM
Dolsten MikaelPresident R&DMay 18Sale37.7895,3533,602,681174,918May 19 05:37 PM
DAMICO JENNIFER B.SVP & ControllerApr 29Sale38.352,18183,6419,647May 01 03:56 PM
JOHNSON RADY AExecutive Vice PresidentApr 29Sale38.3613,125503,47563,940May 01 03:56 PM
ROGERS DAWNExecutive Vice PresidentApr 29Sale38.1313,000495,6904,823May 01 03:56 PM
LANKLER DOUGLAS MExecutive Vice PresidentApr 29Sale37.8565,0002,460,37278,276May 01 03:56 PM
PFIZER INC10% OwnerMar 16Buy16.00312,5005,000,0001,481,719Mar 16 07:15 PM
GOETTLER MICHAELGroup PresidentFeb 28Option Exercise27.3722,852625,45953,036Mar 03 12:54 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3715,996437,81187,956Mar 03 12:54 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3738,8481,063,270172,542Mar 03 12:54 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 28Option Exercise27.3737,9341,038,254140,256Mar 03 12:54 PM
ROGERS DAWNExecutive Vice PresidentFeb 28Option Exercise27.3717,824487,84330,045Mar 03 12:54 PM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.3791,4082,501,837222,496Mar 03 12:55 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37100,5482,751,999504,427Mar 03 12:55 PM
BOURLA ALBERTChairman & CEOFeb 28Option Exercise27.3733,135906,905232,888Mar 03 12:49 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3727,422750,540140,744Mar 03 12:49 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37173,6754,753,485556,084Mar 03 12:49 PM
YOUNG JOHN DGroup PresidentFeb 26Option Exercise34.59144,9285,013,060503,738Feb 28 07:32 PM
ROGERS DAWNExecutive Vice PresidentFeb 26Option Exercise34.5915,097522,20524,995Feb 28 07:28 PM
SUSMAN SALLYExecutive Vice PresidentFeb 26Option Exercise34.5972,4642,506,530180,558Feb 28 07:28 PM
JOHNSON RADY AExecutive Vice PresidentFeb 26Option Exercise34.5933,4141,155,79093,211Feb 28 07:24 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 26Option Exercise34.5988,5673,063,533189,936Feb 28 07:25 PM
GOETTLER MICHAELGroup PresidentFeb 26Option Exercise34.5920,129696,26245,557Feb 28 07:22 PM
Hwang AngelaGroup PresidentFeb 26Option Exercise34.5914,493501,31332,470Feb 28 07:22 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 26Option Exercise34.59144,9285,013,060482,320Feb 28 07:19 PM
BOURLA ALBERTChairman & CEOFeb 26Option Exercise34.5988,5673,063,533274,479Feb 28 07:16 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 26Option Exercise34.5924,155835,521131,196Feb 28 07:15 PM
Gottlieb ScottDirectorJan 30Buy37.001,00036,9974,000Jan 31 08:06 AM